Press coverage about Cambrex Corporation (NYSE:CBM) has trended somewhat positive on Tuesday, Accern Sentiment Analysis reports. Accern ranks the sentiment of news coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Cambrex Corporation earned a media sentiment score of 0.13 on Accern’s scale. Accern also assigned news coverage about the biotechnology company an impact score of 46.4479016437754 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Several brokerages recently weighed in on CBM. BidaskClub upgraded Cambrex Corporation from a “hold” rating to a “buy” rating in a research report on Friday, August 4th. ValuEngine upgraded Cambrex Corporation from a “hold” rating to a “buy” rating in a research report on Tuesday, August 22nd. Finally, Zacks Investment Research downgraded Cambrex Corporation from a “buy” rating to a “hold” rating in a research report on Tuesday, July 4th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the stock. Cambrex Corporation presently has an average rating of “Hold” and an average price target of $65.67.
Shares of Cambrex Corporation (CBM) traded down 3.84% during trading on Tuesday, reaching $51.40. The company’s stock had a trading volume of 161,689 shares. Cambrex Corporation has a 12-month low of $38.30 and a 12-month high of $62.95. The stock has a market cap of $1.68 billion, a P/E ratio of 18.72 and a beta of 2.28. The stock’s 50-day moving average is $53.21 and its 200-day moving average is $55.53.
Cambrex Corporation (NYSE:CBM) last issued its quarterly earnings results on Friday, August 4th. The biotechnology company reported $0.76 earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.76. Cambrex Corporation had a return on equity of 24.25% and a net margin of 17.70%. The firm had revenue of $134.55 million during the quarter, compared to analyst estimates of $136.82 million. During the same quarter in the previous year, the company posted $0.68 earnings per share. The company’s revenue was up 13.4% compared to the same quarter last year. Equities research analysts anticipate that Cambrex Corporation will post $3.08 earnings per share for the current fiscal year.
In other Cambrex Corporation news, CEO Steven M. Klosk sold 4,000 shares of Cambrex Corporation stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $54.96, for a total transaction of $219,840.00. Following the completion of the sale, the chief executive officer now owns 87,328 shares of the company’s stock, valued at $4,799,546.88. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Steven M. Klosk sold 12,000 shares of Cambrex Corporation stock in a transaction dated Friday, September 1st. The stock was sold at an average price of $51.53, for a total value of $618,360.00. Following the sale, the chief executive officer now directly owns 95,328 shares of the company’s stock, valued at approximately $4,912,251.84. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 28,000 shares of company stock valued at $1,574,880. Corporate insiders own 2.48% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Cambrex Corporation (CBM) Earning Somewhat Favorable Press Coverage, Report Shows” was posted by Week Herald and is the property of of Week Herald. If you are reading this report on another site, it was stolen and republished in violation of international trademark and copyright legislation. The legal version of this report can be read at https://weekherald.com/2017/10/17/cambrex-corporation-cbm-earning-somewhat-favorable-press-coverage-report-shows.html.
Cambrex Corporation Company Profile
Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.
Receive News & Ratings for Cambrex Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex Corporation and related companies with MarketBeat.com's FREE daily email newsletter.